Aizant

What Aizant does

Aizant Drug Research Solutions Pvt. Ltd. is a Hyderabad-based, privately held pharmaceutical services company founded in 2008 and backed by private equity firm InvAscent. It operates an integrated CDMO/CMO/CRO platform that spans pre-formulation, formulation development, analytical development, regulatory dossier support, clinical trial material and commercial supply manufacturing, bioanalytical and BA/BE clinical research, and (added in 2025) dedicated API research and development. Its service portfolio is anchored by advanced drug-delivery capabilities — hot melt extrusion, spray drying, and high-containment HPAPI handling (OEL Class 4/5 at 0.1 µg/m³) — and is delivered from a single-campus footprint in Hyderabad with a 190-bed clinical unit, 2.5 billion units of annual manufacturing capacity (500M oncology / 2B general), and a 166,374 sq. ft. API R&D facility at Vizianagaram. Aizant is accredited by USFDA, EU GMP, and WHO, and passed a USFDA inspection of its clinical unit 2 in July 2024 with zero Form 483 observations.

Aizant monetizes primarily through fee-for-service CDMO, CMO, and CRO contracts with global pharmaceutical companies, generic manufacturers, biotechs, and specialty pharma clients across the US, Canada, Europe, and ROW. Beyond services, it operates two partnership models: out-licensing of approved and pipeline products to regional partners (with 27 US, 36 EU, 4 Canadian, and 78 ROW approvals), and co-development arrangements that share risks and rewards on complex generics, NCEs, and specialty products. Distribution is direct enterprise sales via a dedicated business development team supplemented by industry events (e.g., DCAT 2025) and content marketing. The company employs 800+ professionals, including a 150+ quality, regulatory, and compliance team. Its board includes former senior operators from Viatris (COO Sanjeev Sethi), Mylan, Sun Pharma, Zydus Cadila, Ranbaxy, Novartis, Nektar, and Pfizer/InnoPharma, supporting credibility for complex generics and NCE engagements. AI/ML capability is referenced at the operational layer (process optimization in API R&D and the ZenVector platform) but is not externally validated as a differentiating customer-facing asset.

Name

Aizant

Legal name

Aizant Drug Research Solutions Pvt. Ltd.

Website

https://aizant.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aizant is a Hyderabad-based integrated CDMO/CMO/CRO offering formulation development, manufacturing, bioanalytical and clinical research, and API R&D services to global pharmaceutical, generic, biotech, and specialty pharma clients across the US, Canada, Europe, and ROW.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO/CMO/CRO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical CDMO services
• Contract manufacturing organization
• Clinical research services
• API development
• Formulation development

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Services: Contract Development and Manufacturing services providing end-to-end pharmaceutical development from API R&D through formulation to commercial manufacturing
2. CMO Services: Contract Manufacturing services for clinical trial materials and commercial supplies, including technology transfer support
3. Clinical Research Services (CRO): Bioanalytical, BA/BE, and clinical trial management services for pharmaceutical companies conducting drug development
4. Out-Licensing: Licensing of developed pharmaceutical products to partners for distribution in US, Canada, Europe, and ROW markets with upfront payments, milestones, and royalties
5. Co-Development: Joint product development with partners sharing risks, costs, and rewards for complex generics, NCEs, and specialty products

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aizant is an integrated pharmaceutical services provider offering Contract Development and Manufacturing Organization (CDMO), Contract Manufacturing Organization (CMO), and Clinical Research Organization (CRO) services, alongside dedicated API Research and Development. The company delivers end-to-end drug development solutions from pre-formulation and formulation development through clinical trials to commercial manufacturing, supported by regulatory dossier compilation and out-licensing capabilities for global markets including the US, Canada, Europe, and ROW.

Product overview

Aizant Drug Research Solutions Pvt. Ltd. is a comprehensive pharmaceutical development company offering an integrated platform of services spanning Contract Development and Manufacturing Organization (CDMO), Contract Manufacturing Organization (CMO), and Clinical Research (CRO) services, along with API Research and Development. The core CDMO services encompass Pre-Formulation, Formulation Development, Analytical Development, and Regulatory Support & Dossier Compilation. The CMO services include Clinical Trial Material manufacturing, Commercial Supplies, and Technology Transfer. The CRO services feature Bioanalytical, BA/BE (Bioavailability/Bioequivalence), and Clinical Trial Services. Additionally, the company offers dedicated API Development services including API R&D Facilities and API Portfolio management. The company also provides partnership models through Co-Development and Out-Licensing services. All these services are designed to provide end-to-end solutions from early-stage R&D through commercial manufacturing, with global regulatory accreditations including USFDA, EU, and WHO.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Development and Manufacturing Organization (CDMO) Services Comprehensive CDMO services integrating research with large-scale production, guiding each phase of product development from pre-formulation to commercial manufacturing. Specializes in orphan drugs, complex niche drugs, NCEs, ANDAs, and 505(b)(2) filings for pharmaceutical and biotech companies.
• Formulation Development Services Transforms innovative concepts into safe, effective, and scalable pharmaceutical products across solid dosage forms, sterile injectables, topical formulations, nasal products, and sterile infusions with advanced drug delivery technologies.
• Pre-Formulation Services Essential first-step services in pharmaceutical product development including solid-state characterization, solubility and stability studies, salt form selection, excipient compatibility testing, and particle size analysis.
• Analytical Development Services Laboratory services supporting the entire drug development lifecycle with physical and chemical testing, stability studies, Type-4 dissolution testing, method development, and impurity profiling.
• Regulatory Support & Dossier Compilation Regulatory affairs services including dossier compilation, regulatory filing and submissions to FDA, EMA, TGA and other global agencies, regulatory strategy development, and ongoing compliance support.
• Contract Manufacturing Organization (CMO) Services State-of-the-art contract manufacturing services for clinical and commercial supply with oncology manufacturing (Block A) capable of 500 million units annually and general manufacturing (Block B) capable of 2 billion units annually.
• Clinical Trial Material (CTM) Manufacturing Tailored manufacturing solutions for Phase I/II through Phase III/IV clinical trials, compliant with GMP and ICH guidelines, with on-time delivery and tailored packaging and labeling solutions.
• Commercial Supplies Scalable manufacturing solutions for market launch with capacity for up to 2 billion units annually for general therapeutics and 500 million units for oncology treatments, including regulatory excellence and packaging solutions.
• Technology Transfer Services Seamless technology transfer from R&D scale to GMP-scale manufacturing with process optimization and comprehensive regulatory filing documentation support.
• Clinical Research (CRO) Services End-to-end clinical research services with over 1,200 clinical studies conducted under GCP, including bioavailability/bioequivalence studies, bioanalytical services, and clinical trial management across phases I-IV.
• Bioanalytical Services Quality bioanalytical services supporting development of Generics, Complex Generics, NCEs, and NDAs with over 500 validated methods using LC-MS/MS and ICP-MS instruments for precise, regulatory-compliant testing.
• Bioavailability and Bioequivalence (BA/BE) Services Comprehensive BA/BE services combining scientific expertise with regulatory knowledge for fast-track approval of generics and new formulations, including clinical studies, PK/PD analysis, and biostatistics.
• Clinical Trial Services End-to-end clinical trial management services including clinical study management, site and patient management, safety monitoring, medical management, and clinical data management compliant with FDA 21 CFR Part 11.
• API Development Services Integrated API R&D and development services focusing on scientific innovation, process understanding, and analytical excellence with strategic route design, reaction optimization, impurity control, and regulatory-aligned documentation.
• API R&D Facilities 166,374 sq. ft. API R&D centre in Modavalasa, Vizianagaram with advanced chemical and analytical laboratories, oncology and HPAPI suite (OEB 4/5), non-GMP kilo lab, and AI/ML-driven process systems.
• API Portfolio Innovation-driven API pipeline covering Oncology, CNS, Metabolic & Endocrine Disorders, Cardiovascular & Renal, Anti-infectives & Anti-virals, and Respiratory & Inflammatory Diseases with capabilities in complex multi-step API synthesis.
• Out-Licensing Services Business model for expanding reach of developed products through partnerships for distribution and commercialization in targeted markets or regions, with customizable licensing agreements for approved and pipeline products in the US, Canada, Europe, and ROW markets.
• Co-Development Services Strategic partnership model for co-creating and bringing innovative pharmaceutical products to market, with shared risks and rewards for complex generics, NCEs, and specialty products.

Quantifiable outcome

• Zero 483 observations in USFDA clinical facility inspection (2024)
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sai Life Sciences: India-based CRO/CDMO spanning discovery, API development, and formulation services for global pharma. Highly comparable on API + formulation integration and India-base model; similar mid-tier scale and customer mix to Aizant.
• Jubilant Biosys: India-based integrated drug discovery and development CRO/CDMO with formulation and API capabilities. Comparable in service mix (CRO + CDMO + API) and India base; smaller commercial manufacturing footprint than Aizant.
• Piramal Pharma Solutions: India-headquartered CDMO offering integrated drug development and manufacturing across APIs, formulations, and complex generics. Directly comparable on service portfolio, India footprint, and complex-generic orientation; larger capacity and broader global reach than Aizant.
• Aragen Life Sciences (formerly GVK Biosciences): India-headquartered CRO/CDMO offering discovery, development, and manufacturing services including API and formulation. Comparable service breadth and India-base delivery model, with larger discovery footprint than Aizant.
• Syngene International: India-headquartered integrated CRO/CDMO offering discovery, development, and manufacturing services to global pharma. Most direct comparable given overlapping CDMO/CMO/CRO scope, India base, and global pharma client base, though materially larger in scale and publicly listed.
• Dr. Reddy's Custom Pharmaceutical Services: The CDMO arm of Dr. Reddy's Laboratories offering API and finished dosage development and manufacturing. Overlaps with Aizant on formulation, API, and CMO services; materially larger and backed by a global branded generics business.

Broad incumbents

• Lonza Group: Switzerland-based global CDMO leader with API, biologics, and drug-product capabilities. Most relevant global incumbent benchmark for small-molecule API CDMO and complex formulation work similar to Aizant's HPAPI/onco focus.
• Catalent: Global CDMO with strong formulation and clinical supply capabilities, including softgel and oral dose technologies. Comparable on formulation development, clinical supply, and global pharma customer overlap with Aizant; materially larger.
• Divi's Laboratories: One of India's largest API manufacturers with growing CDMO/CMO presence serving global generics and innovators. Relevant for API capabilities that overlap with Aizant's API R&D vertical; significantly larger and a market leader in APIs.
• WuXi AppTec / WuXi STA: Global CRO/CDMO with extensive small-molecule API and formulation capabilities, including India/China delivery. Comparable in service breadth and global pharma client base; substantially larger and a global benchmark for integrated CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/aizant
• LinkedInlinkedin.com/company/aizant-drug-research-solutions-pvt.-ltd.-hyderabad

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aizant